

To: (10)(2e) (10)(2e) (10)(2e) @ecdc.europa.eu
Cc: (10)(2e) (10)(2e) (10)(2e) @rivm.nl; (10)(2e) (10)(2e) @ecdc.europa.eu; (10)(2e)
 (10)(2e) (10)(2e) @ecdc.europa.eu
From: (10)(2e) (10)(2e)
Sent: Tue 5/5/2020 9:28:09 AM
Subject: RE: REMINDER - deadline today: Short survey on use of evaluation data submitted to ECDC Extranet
Received: Tue 5/5/2020 9:28:10 AM

Hi,

I answered four of those.

(10)(2e)

From: (10)(2e) (10)(2e) <(10)(2e)@ecdc.europa.eu>
Sent: dinsdag 5 mei 2020 11:26
To: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl> (10)(2e) (10)(2e) @ecdc.europa.eu; (10)(2e) (10)(2e) <(10)(2e)@ecdc.europa.eu>
Subject: REMINDER - deadline today: Short survey on use of evaluation data submitted to ECDC Extranet

Dear (10)(2e)

This is a kind reminder that the **deadline** for the [short online survey](#) (5 simple questions) on wider sharing of information provided to ECDC's extranet **is today**.

Thanks a lot for your reply that is important for us!

Best wishes

(10)(2e)



(10)(2e) (10)(2e)
 (10)(2e)
 (10)(2e)
 Surveillance, PHF
 Phone: (10)(2e)
 (10)(2e)@ecdc.europa.eu

**European Centre for
Disease Prevention and Control (ECDC)**

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone (10)(2e)

www.ecdc.europa.eu

Follow ECDC on:



From: (10)(2e) (10)(2e) <(10)(2e)@ecdc.europa.eu>
Sent: 02 May 2020 18:14
To: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Subject: Short survey on use of evaluation data submitted to ECDC Extranet

Dear (10)(2e)

Thank you again for providing your evaluation results. Your results or a less detailed derived form, are likely to be useful for a wider audience, and we have received repeated requests about this.

For that reason, I would like to ask you to provide your view and/or permission to do so and in what form. You can provide this through [a short online survey](#) (5 questions), that will allow us to collect the replies from all data providers efficiently.

Please find here the link to the data sharing survey: <https://ec.europa.eu/eusurvey/runner/AssayEvaluationResultWiderSharing>.

We very much appreciate your reply, if possible, **by Tue 5 May**.

Thanks a lot in advance !
Best wishes 😊

(10)(2e)

P.S. please note that we will send you an email per report shared to allow you an individual survey reply (if necessary).

Dr (10)(2e) (10)(2e)

(10)(2e)

Surveillance, PHF

(10)(2e)



From: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>

Sent: 21 April 2020 17:49

To: (10)(2e) (10)(2e) <(10)(2e)@ecdc.europa.eu> (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@who.int>; (10)(2e) <(10)(2e)@who.int>; (10)(2e) <(10)(2e)@who.int>; (10)(2e) <(10)(2e)@who.int>

Subject: Netherlands: nation-wide validation data POCT SARS-CoV-2 serology

Dear all,

I'm very pleased to share with you all, this week's overview of validation of SARS-CoV-2 POCT immune-assays in the Netherlands. All labs have given permission to share with ECDC and WHO. The contributing labs can be found at the beginning of the report. Unfortunately it is mostly in Dutch but the summarizing note is in English. It is important to read the context.

The report is updated on a weekly basis if more data becomes available. The Dutch Taskforce for SARS-CoV-2 serology together with the national outbreak management team has given a negative advice to the Dutch government about the use of POCT in most contexts.

I'm happy to answer any questions,

Best wishes (10)(2e)

Ps. We are working on one for ELISA as well.

(10)(2e) (10)(2e)
(10)(2e)

verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to *health and sustainability*

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.